ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

ATXS Astria Therapeutics Inc

9.50
0.32 (3.49%)
01 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Astria Therapeutics Inc ATXS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.32 3.49% 9.50 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
9.15 9.02 9.83 9.50 9.18
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
09/4/202407:00BWAstria Therapeutics Appoints Sunil Agarwal to Its Board of..
03/4/202415:10BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
25/3/202406:30BWAstria Therapeutics Announces Positive Initial..
05/3/202415:10BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
04/3/202416:22EDGAR2Form 8-K - Current report
04/3/202416:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202415:10BWAstria Therapeutics Reports Fourth Quarter and Full Year..
04/3/202415:02EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202407:00BWAstria Therapeutics to Present at Upcoming American Academy..
14/2/202414:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202407:36EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202407:00BWAstria Therapeutics to Present at Upcoming Oppenheimer 34th..
05/2/202415:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
31/1/202408:00EDGAR2Form 8-K - Current report
31/1/202407:59EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/1/202416:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202408:08BWAstria Therapeutics Announces Pricing of $125 Million..
30/1/202405:01EDGAR2Form 8-K - Current report
29/1/202415:39EDGAR2Form 144 - Report of proposed sale of securities
16/1/202415:18EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/1/202407:30EDGAR2Form 8-K - Current report
02/1/202415:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
28/12/202313:09EDGAR2Form S-3/A - Registration statement under Securities Act of..
20/12/202315:30EDGAR2Form 8-K - Current report
15/12/202307:30EDGAR2Form S-3 - Registration statement under Securities Act of..
04/12/202315:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
27/11/202307:00BWAstria Therapeutics to Present STAR-0215 Data at the 2023..
21/11/202307:00BWAstria Therapeutics to Present at Upcoming 6th Annual..
13/11/202315:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202307:06EDGAR2Form 8-K - Current report
13/11/202307:00BWAstria Therapeutics Reports Third Quarter Financial Results..
10/11/202307:00BWAstria Therapeutics Presents New Phase 1a Data Confirming..
09/11/202307:00BWAstria Therapeutics to Present at Upcoming Jefferies London..
03/11/202307:10BWAstria Therapeutics to Present New STAR-0215 Data at the..
02/11/202315:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
30/10/202307:00BWAstria Therapeutics to Report Third Quarter 2023 Financial..
12/10/202316:04EDGAR2Form 8-K - Current report
12/10/202316:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/10/202307:00EDGAR2Form 8-K - Current report
11/10/202318:14BWAstria Therapeutics Announces Pricing of $64 Million..
11/10/202316:14EDGAR2Form 8-K - Current report
11/10/202316:10BWAstria Therapeutics Announces Exclusive Worldwide License..

Su Consulta Reciente

Delayed Upgrade Clock